Liana Gercheva-Kyuchukova

TL;DR: Once‐monthly subcutaneous administration of fitusiran resulted in dose‐dependent lowering of the antithrombin level and increased thrombin generation in participants with hemophilia A or B who did not have inhibitory alloantibodies.

TL;DR: Fitusiran, an investigational small interfering RNA therapy, reduces antithrombin production to rebalance hemostasis in people with hemophilia A or B, with or without inhibitors as discussed by the authors.

TL;DR: 12 month data from a randomized controlled phase III trial comparing the novel, long-acting Ropeginterferon alfa-2b with hydroxyurea (HU) in PV patients is reported, formally assessing efficacy, safety and tolerability.

TL;DR: Hmatologic and molecular responses and safety results after 5 years of long-term interferon alfa treatment with pegylated alfa-2b are reported.

TL;DR: Clinical data from the phase III PROUD/CONTI-PV trials are reported with an additional emphasis on the first comprehensive, prospective, randomized, controlled genomic profiling including not only JAK2V617F, but longitudinal targeted sequencing to identify non-JAK somatic mutations and chromosomal aberrations.